Irreversible Pancreatic Atrophy as a Novel Late Toxic Effect of Lenvatinib in Hepatocellular Carcinoma Treatment
Hepatocellular carcinoma (HCC) remains one of the most aggressive malignancies globally, accounting for significant cancer-related mortality. The development of molecular targeted therapies, such as lenvatinib, has expanded first-line treatment options for unresectable HCC. Lenvatinib, an oral multikinase inhibitor approved in 2018, targets vascular endothelial growth factor receptors (VEGFR1–3), fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. Its anti-angiogenic and anti-tumor properties have demonstrated efficacy in HCC management. However, its safety profile includes common adverse events such as hypertension, proteinuria, hypothyroidism, diarrhea, and alopecia. This report highlights a previously unrecognized late toxic effect of lenvatinib: irreversible pancreatic atrophy, observed in two patients undergoing prolonged treatment.
Case Presentations and Clinical Findings
Patient 1
A patient with HCC received lenvatinib at the standard dose of 12 mg/day. After two months of therapy, the patient developed grade 1 diarrhea. By the third month, pancreatic exocrine insufficiency was diagnosed, characterized by symptoms consistent with malabsorption. Pancreatic enzyme replacement therapy (PERT) was initiated to manage diarrhea. Volumetric analysis of the pancreas, performed using post-processing software (Advantage Workstation, version 4.6; GE Healthcare), revealed a striking 51% reduction in pancreatic volume compared to baseline measurements (Figure 1A and 1B). Despite discontinuation of lenvatinib, pancreatic atrophy persisted, indicating irreversible damage.
Patient 2
A second patient received lenvatinib at 12 mg/day for 12 months. Unlike the first case, this patient did not report diarrhea during treatment. However, routine magnetic resonance imaging (MRI) detected a 30% decrease in pancreatic volume (Figure 1C and 1D). The absence of gastrointestinal symptoms underscores the insidious nature of pancreatic atrophy, which may occur without overt clinical manifestations.
Mechanism Linking Lenvatinib to Pancreatic Atrophy
The anti-angiogenic properties of lenvatinib, mediated through VEGFR inhibition, are hypothesized to disrupt pancreatic microvasculature. Reduced blood flow to the pancreas could lead to ischemia, fibrosis, and eventual atrophy. This mechanism aligns with observations in sorafenib-treated patients, another anti-angiogenic agent associated with pancreatic toxicity.
Preclinical studies demonstrate that VEGF signaling is critical for maintaining the microvascular network of the pancreas. Inhibition of this pathway by lenvatinib may impair endothelial cell survival and capillary integrity, triggering parenchymal degeneration. The irreversible nature of the atrophy suggests cumulative damage from prolonged exposure, highlighting the need for monitoring in long-term therapy.
Comparison with Sorafenib-Induced Pancreatic Toxicity
Sorafenib, the first-line tyrosine kinase inhibitor for HCC, has documented cases of pancreatic atrophy. Hescot et al. (2013) reported two patients with significant pancreatic volume loss after extended sorafenib use, while Li et al. (2015) linked pancreatic atrophy to sorafenib-induced diarrhea. Both drugs share VEGF pathway inhibition, supporting a class-effect hypothesis for pancreatic toxicity.
Notably, the severity of pancreatic atrophy in lenvatinib-treated patients (30–51% volume loss) mirrors findings in sorafenib cases. However, lenvatinib’s broader kinase inhibition profile—including FGFR and PDGFRα—may exacerbate tissue vulnerability due to impaired repair mechanisms. Fibroblast growth factor signaling, for instance, plays a role in tissue regeneration, and its inhibition could amplify vascular compromise.
Clinical Implications and Monitoring Strategies
-
Pancreatic Exocrine Insufficiency (PEI):
Symptoms such as diarrhea, weight loss, and malnutrition may indicate PEI. Early diagnosis via fecal elastase testing or imaging is critical. Pancreatic enzyme replacement therapy can alleviate symptoms but does not reverse structural damage. -
Imaging-Based Surveillance:
Regular volumetric MRI or computed tomography (CT) enables quantitative assessment of pancreatic volume. The Advantage Workstation tool used in this study provides precise measurements, detecting subclinical atrophy before functional impairment arises. -
Risk-Benefit Evaluation:
While lenvatinib demonstrates robust anti-tumor activity, clinicians must weigh its benefits against the risk of irreversible organ damage. Dose adjustments or alternative therapies may be warranted in patients with predisposing factors for pancreatic dysfunction.
Pancreatic Atrophy as a Surrogate Efficacy Marker
Paradoxically, pancreatic atrophy may correlate with treatment efficacy. The anti-angiogenic effects responsible for pancreatic toxicity also suppress tumor vascularization, potentially reflecting successful target engagement. In Patient 2, significant tumor shrinkage coincided with pancreatic volume loss (Figure 1C and 1D), suggesting a parallel between therapeutic response and collateral tissue damage. Further studies are needed to validate this association.
Limitations and Unanswered Questions
The irreversible nature of lenvatinib-induced pancreatic atrophy raises concerns about its long-term safety. Key unresolved issues include:
- Threshold for Toxicity: Minimum treatment duration or cumulative dose associated with pancreatic damage.
- Predisposing Factors: Patient-specific variables (e.g., preexisting pancreatic insufficiency) that increase susceptibility.
- Reversibility: Whether early intervention can mitigate progression to irreversible atrophy.
Conclusion
This report identifies irreversible pancreatic atrophy as a novel late adverse effect of lenvatinib in HCC patients. The observed 30–51% reduction in pancreatic volume, quantified through advanced imaging techniques, underscores the importance of proactive monitoring during long-term therapy. Clinicians should consider pancreatic surveillance protocols akin to those for renal or thyroid dysfunction. Future research must delineate the pathophysiological mechanisms and explore strategies to preserve pancreatic function without compromising anti-tumor efficacy.
DOI address: doi.org/10.1097/CM9.0000000000000690
Was this helpful?
0 / 0